extract: 2025-03-01-medicare-prior-authorization-glp1-near-universal

Pentagon-Agent: Ganymede <F99EBFA6-547B-4096-BEEA-1D59C3E4028A>

domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md

@@ -23,6 +23,12 @@ The competitive dynamics (Lilly vs. Novo vs. generics post-2031) will drive pric
 
 Real-world persistence data from 125,474 commercially insured patients shows the chronic use model fails not because patients choose indefinite use, but because most cannot sustain it: only 32.3% of non-diabetic obesity patients remain on GLP-1s at one year, dropping to approximately 15% at two years. This creates a paradox for payer economics—the "inflationary chronic use" concern assumes sustained adherence, but the actual problem is insufficient persistence. Under capitation, payers pay for 12 months of therapy ($2,940 at $245/month) for patients who discontinue and regain weight, capturing net cost with no downstream savings from avoided complications. The economics only work if adherence is sustained AND the payer captures downstream benefits—with 85% discontinuing by two years, the downstream cardiovascular and metabolic savings that justify the cost never materialize for most patients.
 
+
+### Additional Evidence (extend)
+*Source: [[2025-03-01-medicare-prior-authorization-glp1-near-universal]] | Added: 2026-03-15*
+
+MA plans are actively restricting GLP-1 access through near-universal prior authorization (up from <5% to 100% in 2 years) even though they bear full risk and would theoretically benefit from prevention. This suggests the inflationary cost impact is driven not just by chronic use economics but by payer resistance creating access friction that may worsen adherence and reduce the preventive value that would justify coverage.
+
 ---
 
 Relevant Notes:

domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md

@@ -47,6 +47,12 @@ This data comes from commercially insured populations (younger, fewer comorbidit
 
 No data yet on whether payment model affects persistence—does being in an MA plan with care coordination improve adherence vs. fee-for-service? This is directly relevant to value-based care design.
 
+
+### Additional Evidence (extend)
+*Source: [[2025-03-01-medicare-prior-authorization-glp1-near-universal]] | Added: 2026-03-15*
+
+Prior authorization requirements escalated to nearly 100% for GLP-1s under MA by 2025. If PA creates delays and access friction, it may further worsen the already-poor adherence rates (15% at 2 years for obesity patients). The PA barrier could be both a response to poor persistence (plans restricting access because patients don't stay on therapy) and a cause of poor persistence (administrative burden leading to abandonment).
+
 ---
 
 Relevant Notes:

domains/health/value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk.md

@@ -29,6 +29,12 @@ PACE represents the extreme end of value-based care alignment—100% capitation
 
 GLP-1 persistence data illustrates why value-based care requires risk alignment: with only 32.3% of non-diabetic obesity patients remaining on GLP-1s at one year (15% at two years), the downstream savings that justify the upfront drug cost never materialize for 85% of patients. Under fee-for-service, the pharmacy benefit pays the cost but doesn't capture the avoided hospitalizations. Under partial risk (upside-only), providers have no incentive to invest in adherence support because they don't bear the cost of discontinuation. Only under full risk (capitation) does the entity paying for the drug also capture the downstream savings—but only if adherence is sustained. This makes GLP-1 economics a test case for whether value-based care can solve the "who pays vs. who benefits" misalignment.
 
+
+### Additional Evidence (confirm)
+*Source: [[2025-03-01-medicare-prior-authorization-glp1-near-universal]] | Added: 2026-03-15*
+
+MA plans bearing full capitated risk increased GLP-1 prior authorization from <5% to nearly 100% in two years despite strong evidence that coverage would reduce long-term costs through kidney disease prevention (24% reduction in progression) and cardiovascular protection. This demonstrates that even full-risk capitation doesn't overcome short-term cost management incentives when drugs cost $1000+/month upfront.
+
 ---
 
 Relevant Notes:

inbox/archive/.extraction-debug/2025-03-01-medicare-prior-authorization-glp1-near-universal.json

@@ -0,0 +1,32 @@
+{
+  "rejected_claims": [
+    {
+      "filename": "medicare-advantage-prior-authorization-escalation-demonstrates-capitation-incentivizes-short-term-cost-avoidance-over-long-term-prevention.md",
+      "issues": [
+        "missing_attribution_extractor"
+      ]
+    },
+    {
+      "filename": "prior-authorization-functions-as-invisible-formulary-exclusion-by-creating-access-friction-without-coverage-denial.md",
+      "issues": [
+        "missing_attribution_extractor"
+      ]
+    }
+  ],
+  "validation_stats": {
+    "total": 2,
+    "kept": 0,
+    "fixed": 2,
+    "rejected": 2,
+    "fixes_applied": [
+      "medicare-advantage-prior-authorization-escalation-demonstrates-capitation-incentivizes-short-term-cost-avoidance-over-long-term-prevention.md:set_created:2026-03-15",
+      "prior-authorization-functions-as-invisible-formulary-exclusion-by-creating-access-friction-without-coverage-denial.md:set_created:2026-03-15"
+    ],
+    "rejections": [
+      "medicare-advantage-prior-authorization-escalation-demonstrates-capitation-incentivizes-short-term-cost-avoidance-over-long-term-prevention.md:missing_attribution_extractor",
+      "prior-authorization-functions-as-invisible-formulary-exclusion-by-creating-access-friction-without-coverage-denial.md:missing_attribution_extractor"
+    ]
+  },
+  "model": "anthropic/claude-sonnet-4.5",
+  "date": "2026-03-15"
+}

inbox/archive/2025-03-01-medicare-prior-authorization-glp1-near-universal.md

@@ -7,9 +7,13 @@ date: 2025-03-01
 domain: health
 secondary_domains: []
 format: article
-status: unprocessed
+status: enrichment
 priority: medium
 tags: [glp-1, prior-authorization, medicare-advantage, formulary, access-barriers]
+processed_by: vida
+processed_date: 2026-03-15
+enrichments_applied: ["value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk.md", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md", "glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content
@@ -44,3 +48,12 @@ Analysis of GLP-1 coverage and prior authorization requirements under Medicare A
 PRIMARY CONNECTION: [[value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk]]
 WHY ARCHIVED: Near-universal PA for GLP-1s under MA demonstrates that capitation alone doesn't align incentives for prevention — MA plans still manage to short-term cost metrics
 EXTRACTION HINT: Focus on the tension between theoretical capitation incentives (cover prevention → save money) and actual MA behavior (restrict access → minimize short-term spend)
+
+
+## Key Facts
+- Injectable semaglutide (Ozempic) covered by 98.0% of MA plans in 2025
+- Tirzepatide (Mounjaro) covered by 96.2% of MA plans in 2025
+- Oral semaglutide covered by 84.8% of MA plans in 2025
+- Dulaglutide covered by 87.5% of MA plans in 2025
+- Only 13 state Medicaid programs covered GLP-1s for obesity as of January 2026
+- GLP-1s for weight loss/obesity remain excluded under Medicare Part D until BALANCE model demonstration launches July 2026